S
Stijn W.T.P.J. Heijmink
Researcher at Netherlands Cancer Institute
Publications - 67
Citations - 4207
Stijn W.T.P.J. Heijmink is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 22, co-authored 60 publications receiving 3704 citations. Previous affiliations of Stijn W.T.P.J. Heijmink include Radboud University Nijmegen Medical Centre & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting
Louise Dickinson,Louise Dickinson,Louise Dickinson,Hashim U. Ahmed,Hashim U. Ahmed,Clare Allen,Jelle O. Barentsz,B. Carey,Jurgen J. Fütterer,Stijn W.T.P.J. Heijmink,Peter Hoskin,Alex Kirkham,Anwar R. Padhani,Raj Persad,Philippe Puech,Shonit Punwani,Aslam Sohaib,Bertrand Tombal,Arnauld Villers,Jan van der Meulen,Jan van der Meulen,Mark Emberton,Mark Emberton,Mark Emberton +23 more
TL;DR: Consensus was reached on a number of areas related to the conduct, interpretation, and reporting of mpMRI for the detection, localisation, and characterisation of prostate cancer.
Journal ArticleDOI
Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging
Caroline M. A. Hoeks,Jelle O. Barentsz,Thomas Hambrock,Derya Yakar,Diederik M. Somford,Stijn W.T.P.J. Heijmink,Tom W. J. Scheenen,Pieter C. Vos,Henkjan J. Huisman,Inge M. van Oort,J. Alfred Witjes,Arend Heerschap,Jurgen J. Fütterer +12 more
TL;DR: Suggestions for a general minimal protocol for multiparametric MR imaging of the prostate based on the literature and the authors' experience are presented and support techniques, such as computer-aided diagnosis, are needed to obtain a fast, cost-effective, easy, and more reproducible prostate cancer diagnosis.
Journal ArticleDOI
Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging
Jurgen J. Fütterer,Stijn W.T.P.J. Heijmink,Tom W. J. Scheenen,Jeroen Veltman,Henkjan J. Huisman,Pieter E. Vos,Christina A. Hulsbergen-van de Kaa,J. Alfred Witjes,Paul F M Krabbe,Arend Heerschap,Jelle O. Barentsz +10 more
TL;DR: Compared with use of T2-weighted MR imaging, use of dynamic contrast-enhanced MR imaging and 3D MR spectroscopic imaging facilitated significantly improved accuracy in prostate cancer localization.
Journal ArticleDOI
Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T—Comparison of Image Quality, Localization, and Staging Performance
Stijn W.T.P.J. Heijmink,Jurgen J. Fütterer,Thomas Hambrock,Satoru Takahashi,Tom W. J. Scheenen,Henkjan J. Huisman,Christina A. Hulsbergen-van de Kaa,Ben C. Knipscheer,Lambertus A. Kiemeney,J. Alfred Witjes,Jelle O. Barentsz +10 more
TL;DR: Image quality and localization of prostate cancer localization and staging improved significantly with ERC imaging compared with BAC imaging, and for experienced radiologists, the staging performance was significantly better with E RC imaging.
Journal ArticleDOI
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Elisa A. Rozeman,Alexander M. Menzies,Alexander C.J. van Akkooi,Chandra Adhikari,Carolien Bierman,Bart A. van de Wiel,Richard A. Scolyer,Richard A. Scolyer,Oscar Krijgsman,Karolina Sikorska,Hanna Eriksson,Annegien Broeks,Johannes V. Van Thienen,Alexander Guminski,Alex Torres Acosta,Sylvia ter Meulen,Anne Miek Koenen,Linda J.W. Bosch,Kerwin F. Shannon,Kerwin F. Shannon,Loes M. Pronk,María Jesús González González,Sydney Ch'ng,Sydney Ch'ng,Lindsay G Grijpink-Ongering,Jonathan R. Stretch,Jonathan R. Stretch,Stijn W.T.P.J. Heijmink,Harm van Tinteren,John B. A. G. Haanen,Omgo E. Nieweg,Omgo E. Nieweg,Willem M.C. Klop,Charlotte L. Zuur,Robyn P. M. Saw,Robyn P. M. Saw,Winan J. van Houdt,Daniel S. Peeper,Andrew J. Spillane,Johan Hansson,Ton N. Schumacher,Georgina V. Long,Christian U. Blank +42 more
TL;DR: The aim of the OpACIN-neo trial was to identify a dosing schedule of ipilimumab plus nivolumab that is less toxic but equally effective and the proportion of patients achieving a radiological objective response and pathological response at 6 weeks.